1 Nov

Flexibility crucial to growing appeal of big money drug royalty transactions, says leading deal-maker

Fresh off last week’s deal with AnaptysBio, Sagard Healthcare Royalty Partners’ Ali Alagheband tells IAM why drug royalty transactions are proving increasingly attractive for life sciences innovators and explains how he selects assets for investment.

Adam Houldsworth

Author | Life sciences reporter

[email protected]

Adam Houldsworth